计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T127039-5mg |
5mg |
现货 ![]() |
| |
| T127039-25mg |
25mg |
现货 ![]() |
| |
| T127039-100mg |
100mg |
期货 ![]() |
|
| 英文别名 | 4-benzyl-2-(naphthalen-1-yl)-(1,2,4)thiadiazolidine-3,5-dione | AKOS006237680 | NSC800950 | NSC-800950 | HY-14872 | BDBM50166940 | Q747Y6TT42 | A857027 | FT-0700382 | HMS3673G17 | Tideglusib, >=98% (HPLC) | SB19268 | Tideglusib(NP-031112) | 4-BENZYL-2-(A- |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Tideglusib |
| 生化机理 | Tideglusib又名NP031112或NP-12,是糖原合酶激酶-3(GSK3)的一种强效非ATP竞争性抑制剂,GSK3是干细胞研究和神经退行性疾病中的一种重要激酶。目前,它正处于治疗阿尔茨海默病和进行性核上性麻痹(PSP)的临床试验阶段。Tideglusib 可减少 tau 蛋白的磷酸化和淀粉样斑块的积累,减少海马和内视网膜皮层神经元的损失,改善空间记忆障碍。它还在多种动物模型中显示出神经保护和抗炎活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 糖原合酶激酶-3 beta 抑制剂 |
| 产品介绍 |
Tideglusib(NP-031112)是不可逆的非ATP竞争性GSK-3β抑制剂,IC50为60 nM。 Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. |
| 纯度 | ≥98% |
| ALogP | 4.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione |
| INCHI | 1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2 |
| InChi Key | PMJIHLSCWIDGMD-UHFFFAOYSA-N |
| Smiles | C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43 |
| Isomeric SMILES | C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43 |
| PubChem CID | 11313622 |
| 分子量 | 334.39 |
| 溶解性 | DMSO 1 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 分子量 | 334.400 g/mol |
| XLogP3 | 4.300 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 3 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 334.078 Da |
| 单同位素质量Monoisotopic Mass | 334.078 Da |
| 拓扑极表面积Topological Polar Surface Area | 65.900 Ų |
| 重原子数Heavy Atom Count | 24 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 492.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| WGK Germany | 3 |
|---|
| 1. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, Santos A, Perez-Castillo A. (2007) NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders.. J Neurosci, 27 (21): (5766-76). [PMID:17522320] |
| 2. Martinez A, Gil C, Perez DI. (2011) Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.. Int J Alzheimers Dis, 2011 (280502). [PMID:21760986] |
| 3. Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M. (2012) Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.. J Biol Chem, 287 (2): (893-904). [PMID:22102280] |
| 4. del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, León T. (2013) Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.. J Alzheimers Dis, 33 (1): (205-15). [PMID:22936007] |
| 5. Neves VC, Babb R, Chandrasekaran D, Sharpe PT. (2017) Promotion of natural tooth repair by small molecule GSK3 antagonists.. Sci Rep, 7 (39654). [PMID:28067250] |
| 6. Yang T, Zhang T, Guan XN, Dong Z, Lan L, Yang S, Yang CG. (2020) Tideglusib and Its Analogues As Inhibitors of Staphylococcus aureus SrtA.. J Med Chem, 63 (15): (8442-8457). [PMID:32639734] |